Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H10Cl2O3 |
Molecular Weight | 297.133 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=C(OC2=C(Cl)C=C(Cl)C=C2)C=CC=C1
InChI
InChIKey=IDKAXRLETRCXKS-UHFFFAOYSA-N
InChI=1S/C14H10Cl2O3/c15-10-5-6-13(11(16)8-10)19-12-4-2-1-3-9(12)7-14(17)18/h1-6,8H,7H2,(H,17,18)
DescriptionSources: http://www.ndrugs.com/?s=flenacCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2937024
https://www.ncbi.nlm.nih.gov/pubmed/970297
Sources: http://www.ndrugs.com/?s=flenac
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2937024
https://www.ncbi.nlm.nih.gov/pubmed/970297
Fenclofenac (Flenac) is a non-steroidal anti-inflammatory drug previously used in rheumatism. Fenclofenac was shown to possess anti-inflammatory, antinociceptive and antipyretic properties. Flenac is an acetic acid nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Flenac is used to treat pain, dysmenorrhea, ocular inflammation, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and actinic keratosis.
It has mild immunosuppressive effects and may displace thyroid hormone from its binding protein. The antiinflammatory effects of Flenac are believed to be due to inhibition of both leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2), leading to the peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of Flenac. Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation. Fenclofenac, despite passing animal toxicity tests in 10 animal species (mice, rats, guinea pigs, ferrets, rabbits, cats, dogs, pigs, horses, and monkeys), produced severe liver toxicity in humans. Due to its side effects it was withdrawn from the UK in 1984.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Triiodothyronine metabolism Sources: https://www.ncbi.nlm.nih.gov/pubmed/2912709 |
69.0 µM [IC50] | ||
Target ID: CHEMBL2094253 Sources: http://www.ndrugs.com/?s=flenac&t=actions |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Flenac Approved UseAcute and long-term use in the relief of signs and symptoms of ankylosing spondylitis (delayed-release tablets); acute treatment of migraine attacks with or without aura in adults (oral solution); relief of mild to moderate pain (immediate-release capsules and tablets); relief of signs and symptoms of osteoarthritis and rheumatoid arthritis (immediate-release, ER, and delayed-release tablets); treatment of primary dysmenorrhea (immediate-release tablets). |
|||
Sources: http://www.ndrugs.com/?s=flenac |
Palliative | Flenac Approved UseAcute and long-term use in the relief of signs and symptoms of ankylosing spondylitis (delayed-release tablets); acute treatment of migraine attacks with or without aura in adults (oral solution); relief of mild to moderate pain (immediate-release capsules and tablets); relief of signs and symptoms of osteoarthritis and rheumatoid arthritis (immediate-release, ER, and delayed-release tablets); treatment of primary dysmenorrhea (immediate-release tablets). |
||
Palliative | Flenac Approved UseAcute and long-term use in the relief of signs and symptoms of ankylosing spondylitis (delayed-release tablets); acute treatment of migraine attacks with or without aura in adults (oral solution); relief of mild to moderate pain (immediate-release capsules and tablets); relief of signs and symptoms of osteoarthritis and rheumatoid arthritis (immediate-release, ER, and delayed-release tablets); treatment of primary dysmenorrhea (immediate-release tablets). |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ndrugs.com/?s=flenac&t=dosage
Usual Adult Dose for Osteoarthritis
Flenac free acid capsules: 35 mg orally 3 times a day
Flenac potassium immediate-release tablets: 50 mg orally 2 or 3 times a day
Flenac sodium enteric-coated tablets: 50 mg orally 2 or 3 times a day or 75 mg orally 2 times a day
Maximum dose: 150 mg daily
Flenac sodium extended-release tablets: 100 mg orally once a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2912709
Fenclofenac inhibited cellular uptake of T3 in rat H4 hepatoma cells with IC50 69 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
34645-84-6
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
C65643
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
100000081267
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
C012970
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
Y01JW64D01
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
FENCLOFENAC
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
3488
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
252-126-2
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
DTXSID6048830
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
65394
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
SUB07549MIG
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL15677
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY | |||
|
1147
Created by
admin on Fri Dec 15 15:35:00 GMT 2023 , Edited by admin on Fri Dec 15 15:35:00 GMT 2023
|
PRIMARY |
ACTIVE MOIETY